Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this report, a 26-year-old man with folliculitis decalvans unresponsive to standard treatments experienced significant disease clearance after 25 months of systemic photodynamic therapy, marking the first documented use of this therapy for this condition.

This study suggests that increased use of anticancer drugs from 2004 to 2008 has led to higher environmental release, necessitating expanded monitoring and research on their ecotoxicological impacts.

This study found that isolated red light may serve as an alternative for photo-immunotherapy without additional photosensitizers, as it did not reduce keratinocyte differentiation markers or increase photo-oxidative damage, unlike treatment with IL-4 or UVA1/blue light.

This study reported that a 10-week course of clindamycin and rifampicin was commonly used for treating folliculitis decalvans but the evidence on its efficacy remains inconclusive due to the low quality of available studies.

This article suggests considering biologics to stabilize inflammation in moderate to severe folliculitis decalvans, although it reports no new clinical results.